JAK inhibitors like ruxolitinib can lower binding affinity to CCR5 but not stop it. Blocking CCR5 with leronlimab decreases JAK1 and JAK2. Ruxolitinib is used extensively to combat GVHD in stem cell transplants, if it could cure HIV you would see more numerous examples. Ruxolitinib can slow reactivation of reservoirs but does not flush viral reservoirs. So the HIV virus would be lurking in those reservoirs for longer.

In the stem cell transplantation the new cells set up a new immune system that can wipe out many of the old and replace them. GVHD is a fallout from this because it can see the patients own cells as foreign and destroy them. So in a patient with bad GVHD more reservoir cells where HIV can hide will be destroyed. It is possible that in this case all the reservoir cells were destroyed. But in other cases HIV has seemed to disappear then pop back up much later.